AKBA vs. TVTX, JANX, IRON, AGIO, APGE, MESO, VERA, GLPG, KNSA, and SDGR
Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Travere Therapeutics (TVTX), Janux Therapeutics (JANX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Mesoblast (MESO), Vera Therapeutics (VERA), Galapagos (GLPG), Kiniksa Pharmaceuticals (KNSA), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical products" industry.
Akebia Therapeutics vs.
Travere Therapeutics (NASDAQ:TVTX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.
33.9% of Akebia Therapeutics shares are held by institutional investors. 3.8% of Travere Therapeutics shares are held by insiders. Comparatively, 4.1% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Akebia Therapeutics received 333 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 63.24% of users gave Akebia Therapeutics an outperform vote while only 59.44% of users gave Travere Therapeutics an outperform vote.
Akebia Therapeutics has a net margin of -27.07% compared to Travere Therapeutics' net margin of -137.90%. Akebia Therapeutics' return on equity of 0.00% beat Travere Therapeutics' return on equity.
Akebia Therapeutics has lower revenue, but higher earnings than Travere Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Travere Therapeutics had 5 more articles in the media than Akebia Therapeutics. MarketBeat recorded 8 mentions for Travere Therapeutics and 3 mentions for Akebia Therapeutics. Travere Therapeutics' average media sentiment score of 1.52 beat Akebia Therapeutics' score of 0.62 indicating that Travere Therapeutics is being referred to more favorably in the media.
Travere Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.
Travere Therapeutics currently has a consensus target price of $30.62, indicating a potential upside of 70.51%. Akebia Therapeutics has a consensus target price of $6.75, indicating a potential upside of 254.33%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Travere Therapeutics.
Summary
Akebia Therapeutics beats Travere Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Akebia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akebia Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AKBA) was last updated on 3/31/2025 by MarketBeat.com Staff
Buy AKBA Stock Free AKBA Stock Alerts